Anetumab ravtansine (BAY94-9343)

DRUG5 trials

Sponsors

Bayer

Conditions

Medical OncologyMesotheliomaNeoplasmsOvarian Neoplasms

Phase 1

Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

CompletedNCT02696642

Start: 2016-04-14End: 2019-08-19Updated: 2021-07-09

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

CompletedNCT02751918

BayerOvarian Neoplasms

Start: 2016-06-08End: 2019-10-31Updated: 2019-11-22

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

CompletedNCT02824042

BayerMedical Oncology

Start: 2016-09-07End: 2019-08-05Updated: 2020-07-31

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

CompletedNCT03102320

Start: 2017-05-26End: 2021-07-26Updated: 2022-06-30

Phase 2

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

CompletedNCT02610140

BayerMesothelioma

Start: 2015-12-03End: 2019-09-06Updated: 2020-11-04

Related Papers

Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.

2023-04-0328 citations

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.

2022-04-0145 citations

Abstract 4816: Anetumab ravtansine has monotherapy efficacy in mesothelin positive patient-derived NSCLC tumor models and in a syngeneic tumor model in immunocompetent mice

Cancer Research2019-07-011 citations

Abstract 4816: Anetumab ravtansine has monotherapy efficacy in mesothelin positive patient-derived NSCLC tumor models and in a syngeneic tumor model in immunocompetent mice

Experimental and Molecular Therapeutics2019-07-01

Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

Journal of Clinical Oncology2018-05-2016 citations

Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.

Journal of Clinical Oncology2018-05-2010 citations

AB027. PS01.09. In-progress: phase 1b study of anetumab ravtansine in patients with mesothelin-expressing malignancies

Mediastinum2017-01-01

Abstract CT083: A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140)

Cancer Research2016-07-152 citations

Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR).

Journal of Clinical Oncology2016-05-2037 citations

A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140).

Journal of Clinical Oncology2016-05-2020 citations